Genomic Testing for Gemcitabine-Based Treatment of Pancreatic Cancer

J Natl Cancer Inst. 2016 Feb 8;108(5):djv424. doi: 10.1093/jnci/djv424. Print 2016 May.

Authors

Jianliang Zhang¹, Steven N Hochwald²

Affiliations

¹ Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY (JZ, SNH).
² Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY (JZ, SNH). steven.hochwald@roswellpark.org.

PMID: 26857393
DOI: 10.1093/jnci/djv424

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma / genetics*
Adenocarcinoma / mortality*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / genetics*
Carcinoma, Pancreatic Ductal / genetics*
Carcinoma, Pancreatic Ductal / mortality*
Female
Humans
Male
Oxidoreductases / genetics*
Pancreatic Neoplasms / genetics*
Pancreatic Neoplasms / mortality*
Polymorphism, Single Nucleotide*
Sp Transcription Factors / genetics*
Tumor Suppressor Proteins / genetics*

Substances

Biomarkers, Tumor
Sp Transcription Factors
Tumor Suppressor Proteins
Oxidoreductases